| Erin Marchand, MD | |
|
92 W Christmas Blvd, Santa Claus, IN 47579-6044 | |
| (812) 937-4120 | |
| Not Available |
| Full Name | Erin Marchand |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 92 W Christmas Blvd, Santa Claus, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972766236 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01068560A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Home Care | Jasper, IN | Home health agency |
| Heart To Heart Hospice Of Southwest Indiana Llc | Jasper, IN | Hospice |
| Memorial Hospital And Health Care Center | Jasper, IN | Hospital |
| Perry County Memorial Hospital | Tell city, IN | Hospital |
| Deaconess Hospital Inc | Evansville, IN | Hospital |
| Women's Hospital The | Newburgh, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Little Company Of Mary Hospital Of Indiana Inc | 4587578042 | 167 |
News Archive
Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.
Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
A new study shows that diuretic pill Inspra (generic – Eplerenone) cuts down the risk of death and hospitalization among people with mild heart failure. The drug that is widely used to treat advanced heart failure, also has value for people with mild disease, says lead researcher Faiez Zannad, of Nancy University in Nancy, France. The results were reported at the American Heart Association's annual meeting and published simultaneously online in the New England Journal of Medicine.
Peter L. Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD), today said the Food and Drug Administration's (FDA) announcement that it has created a new position—Associate Director for Rare Diseases—in the agency's Center for Drug Evaluation and Research's (CDER) Office of New Drugs (OND) represents an important advance for patients with rare diseases.
› Verified 8 days ago
| Entity Name | Little Company Of Mary Hospital Of Indiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114120128 PECOS PAC ID: 4587578042 Enrollment ID: O20031118000733 |
News Archive
Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.
Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
A new study shows that diuretic pill Inspra (generic – Eplerenone) cuts down the risk of death and hospitalization among people with mild heart failure. The drug that is widely used to treat advanced heart failure, also has value for people with mild disease, says lead researcher Faiez Zannad, of Nancy University in Nancy, France. The results were reported at the American Heart Association's annual meeting and published simultaneously online in the New England Journal of Medicine.
Peter L. Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD), today said the Food and Drug Administration's (FDA) announcement that it has created a new position—Associate Director for Rare Diseases—in the agency's Center for Drug Evaluation and Research's (CDER) Office of New Drugs (OND) represents an important advance for patients with rare diseases.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Marchand, MD 92 W Christmas Blvd, Santa Claus, IN 47579-6044 Ph: (812) 937-4120 | Erin Marchand, MD 92 W Christmas Blvd, Santa Claus, IN 47579-6044 Ph: (812) 937-4120 |
News Archive
Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.
Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
A new study shows that diuretic pill Inspra (generic – Eplerenone) cuts down the risk of death and hospitalization among people with mild heart failure. The drug that is widely used to treat advanced heart failure, also has value for people with mild disease, says lead researcher Faiez Zannad, of Nancy University in Nancy, France. The results were reported at the American Heart Association's annual meeting and published simultaneously online in the New England Journal of Medicine.
Peter L. Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD), today said the Food and Drug Administration's (FDA) announcement that it has created a new position—Associate Director for Rare Diseases—in the agency's Center for Drug Evaluation and Research's (CDER) Office of New Drugs (OND) represents an important advance for patients with rare diseases.
› Verified 8 days ago
Dr. Melinda J Gruber, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 92 W Christmas Blvd, Santa Claus, Santa Claus, IN 47579 Phone: 812-937-4120 Fax: 812-937-7074 |